

alpha kinase, a vector and host cell comprising said nucleic acid.

- III. Claims 7-9, 14-17, drawn to an isolated nucleic acid encoding a mammalian kidney alpha kinase, a vector and host cell comprising said nucleic acid.
- IV. Claims 10-11, 14-17, drawn to an isolated nucleic acid encoding a mammalian skeletal muscle alpha kinase, a vector and host cell comprising said nucleic acid.
- V. Claims 12-13, 14-17, drawn to an isolated nucleic acid encoding a mammalian lymphocyte alpha kinase, a vector acid encoding a mammalian lymphocyte alpha kinase, a vector and host cell comprising said nucleic acid.
- VI. Claims 18-20 and 29, drawn to an isolated melanoma alpha kinase protein and a pharmaceutical composition comprising said alpha kinase.
- VII. Claims 18, 21-22 and 29, drawn to an isolated kidney alpha kinase protein and a pharmaceutical composition comprising said alpha kinase.
- VIII. Claims 18, 23-24 and 29, drawn to an isolated heart alpha kinase protein and a pharmaceutical composition comprising aid alpha kinase.
- IX. Claims 18, 25-26 and 29, drawn to an isolated skeletal muscle alpha kinase protein and a pharmaceutical composition comprising said alpha kinase.
- X. Claims 18, 27-28 and 29, drawn to an isolated lymphocyte alpha kinase protein and a pharmaceutical composition comprising said alpha kinase.
- XI. Claims 30-35, drawn to an isolated antibody against an alpha kinase protein and a cell that produces said antibody.
- XII. Claims 36-37, drawn to a method for treating an animal in need of increased activity of melanoma alpha kinase.
- XIII. Claims 38-39, drawn to a method for treating an animal in need of increased activity of kidney alpha kinase.
- XIV. Claims 40-41, drawn to a method for treating an animal in need of activity of heart alpha kinase.
- XV. Claims 42-43, drawn to a method for treating an animal in need of increased activity of skeletal muscle alpha kinase.


- XVI. Claims 44-45, drawn to a method for treating an animal in need of increased activity of lymphocyte alpha kinase.
- XVII. Claims 46-47, drawn to a method for detecting the presence or activity of an alpha kinase protein.
- XVIII. Claims 48, drawn to a method of testing the ability of a drug to modulate the kinase activity of an alpha kinase protein.

Responsive to the Requirement for restriction, Applicants elect to prosecute the invention of Group II, Claims 4-6, 14-17, drawn to an isolated nucleic acid encoding a mammalian heart alpha kinase, a vector and host cell comprising said nucleic acid.

No fees are believed to be necessitated by the foregoing Response. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or credit any overages.

In view of the above, withdrawal of the Requirement for the Restriction is requested, and an early action on the merits of the Claims is courteously solicited.

Respectfully submitted,


DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800

Date: January 17, 2003